Beacon Pharmaceuticals (DHA:BEACONPHAR) Debt-to-Equity : 1.52 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Beacon Pharmaceuticals Debt-to-Equity?

Beacon Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was BDT7,657 Mil. Beacon Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was BDT1,960 Mil. Beacon Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was BDT6,324 Mil. Beacon Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 1.52.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Beacon Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

DHA:BEACONPHAR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.45 Med: 0.61 Max: 1.52
Current: 1.52

During the past 8 years, the highest Debt-to-Equity Ratio of Beacon Pharmaceuticals was 1.52. The lowest was 0.45. And the median was 0.61.

DHA:BEACONPHAR's Debt-to-Equity is ranked worse than
93.69% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.285 vs DHA:BEACONPHAR: 1.52

Beacon Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Beacon Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beacon Pharmaceuticals Debt-to-Equity Chart

Beacon Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.60

0.47

0.64

1.26

Beacon Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.71	1.05	1.26	1.21	1.52

Competitive Comparison of Beacon Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Beacon Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beacon Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beacon Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Beacon Pharmaceuticals's Debt-to-Equity falls into.

Beacon Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Beacon Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6682.828	+	772.479)	/	5942.024
	=	1.25

Beacon Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7656.777	+	1960.198)	/	6323.897
	=	1.52

Beacon Pharmaceuticals (DHA:BEACONPHAR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Beacon Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Beacon Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Beacon Pharmaceuticals (DHA:BEACONPHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beacon Pharmaceuticals PLC (DHA:BEACONPHAR) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

9/B/2, Toyenbee Circular Road, Motijheel C/A, Beacon Business Centre, Dhaka, BGD, 1223

Website

https://www.beaconpharma.com.bd

Beacon Pharmaceuticals PLC manufactures and markets pharmaceutical products. Its products are used in various therapeutic areas, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, and muscle relaxants. The company exports its products to Europe, America, Australia, Africa, and Asia. The company's products can be segmented as General, Chronic Care, Oncology, and Biotech products.

Beacon Pharmaceuticals (DHA:BEACONPHAR) Headlines

No Headlines